Last $13.79 USD
Change Today -0.25 / -1.78%
Volume 214.4K
ELGX On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 09/22/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

11 Studebaker

Irvine, CA 92618

United States

Phone: 949-595-7200

Fax:

Endologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of aortic disorders. The company’s principal products are intended for the treatment of abdominal aortic aneurysms (AAA). Its AAA products are built on one of two platforms, such as traditional minimally-invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens. Products EVAR Platform The company’s EVAR products include the Endologix AFX Endovascular AAA System (AFX); the VELA Proximal Endograft (VELA); and the Endologix Intuitrak Endovascular AAA System (Intuitrak). Its EVAR products consist of a cobalt chromium alloy stent covered by polytetrafluoroethylene (ePTFE) graft material (Stent Graft); and an accompanying delivery system. The company’s EVAR products consist of its EVAR Stent Graft and catheter delivery system branded under the names, such as Powerlink, IntuiTrak, AFX, and VELA. Within its EVAR platform, AFX is marketed in the United States, Europe, and South America; VELA is approved in the United States; and Intuitrak sales are limited to Japan. EVAS Platform The company’s EVAS product is the Nellix Endovascular Aneurysm Sealing System (Nellix EVAS System). Its EVAS product consists of bilateral covered stents with endobags; a biocompatible polymer injected into the endobags to seal the aneurysm; and a delivery system and polymer dispenser. Its EVAS product is based on the Nellix platform to seal the aneurysm and provide blood flow to the legs through two blood lumens. EVAR and EVAS Extensions and Accessories Aortic Extensions and Limb Extensions: The company offers proximal aortic extensions and limb extensions, which attach to the ‘main body’ of its EVAR Device, allowing physicians to customize it to fit the patient's anatomy. In February 2014, the company launched a new proximal extension, VELA, designed primarily for the treatment of proximal aortic neck anatomies. VELA features a circumferential graft line marker and controlled delivery system that enable predictable deployment and final positional adjustments. Accessories: The company offers various accessories to facilitate the optimal delivery of its EVAR products, including compatible guidewires, snares, and catheter introducer sheaths. Marketing and Sales The company markets and sells its products in the U.S. and in 11 Western European countries (the Great Britain, France, Germany, Italy, Spain, Switzerland, the Netherlands, Austria, Belgium, Luxembourg, and Monaco) through a direct sales force and network of agents. In 14 other European countries, Japan, 9 countries in South America, New Zealand, and Mexico, it sells its EVAR products through independent distributors or agents. As of February 28, 2014, the company marketed its EVAR products in 23 countries outside of the U.S. through a total of 13 independent distributors. It markets its EVAS products through direct sales channels in Europe and its independent agent in New Zealand. The company has applicable regulatory approvals for Mexico, Argentina, Brazil, Chile, Peru, Ecuador, Venezuela, Costa Rica, Panama, and Colombia. Strategy Major elements of the company’s strategy are to focus exclusively on the aorta for the commercialization of innovative products; design and manufacture EVAR and EVAS products that are easy to use and deliver excellent clinical outcomes; design EVAR and EVAS products to expand into complex anatomies; and provide exceptional clinical and technical support to physicians through an experienced and knowledgeable sales and marketing organization. Product Developments and Clinical Trials Nellix EVAS System: The company owns Nellix, Inc. (Nellix). It developed the Nellix EVAS System, a next-generation device, to treat infrarenal AAA. In 2013, the company received CE Mark approval of the Nellix EVAS System. In 2013, it commenced a limited market introduction of the Nellix EVAS System in Europe. In 2013, it received Investigational Device Exemption (IDE) approval in the United States to begin a clinical trial, which commenced in

Page 12Next Page
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ELGX:US $13.79 USD -0.25

ELGX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AtriCure Inc $14.87 USD -0.11
Cardiovascular Systems Inc $26.94 USD +0.08
CryoLife Inc $10.17 USD -0.04
Spectranetics Corp/The $27.53 USD -0.51
Vascular Solutions Inc $23.16 USD -0.30
View Industry Companies
 

Industry Analysis

ELGX

Industry Average

Valuation ELGX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 6.3x
Price/Book 6.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 5.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ENDOLOGIX INC, please visit www.endologix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.